Reproductive Endocrinology and Cell Signaling Laboratory, Department of Integrative Biosciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX 77843, USA.
Biol Reprod. 2013 Mar 28;88(3):77. doi: 10.1095/biolreprod.112.100883. Print 2013 Mar.
Endometriosis is a chronic gynecological disease of reproductive age women characterized by the presence of functional endometrial tissues outside the uterine cavity. Interactions between the endometriotic cells and the peritoneal extracellular matrix proteins (ECM) are crucial mechanisms that allow adhesion of the endometriotic cells into peritoneal mesothelia. Prostaglandin E2 (PGE2) plays an important role in the pathogenesis of endometriosis. In previous studies, we have reported that selective inhibition of PGE2 receptors PTGER2 and PTGER4 decreases survival and invasion of human endometriotic epithelial and stromal cells through multiple mechanisms. Results of the present study indicates that selective inhibition of PTGER2- and PTGER4-mediated PGE2 signaling 1) decreases the expression and/or activity of specific integrin receptor subunits Itgb1 (beta1) and Itgb3 (beta3) but not Itgb5 (beta5), Itga1 (alpha1), Itga2 (alpha2), Itga5 (alpha5), and Itgav (alphav); 2) decreases integrin-signaling components focal adhesion kinase or protein kinase 2 (PTK2) and talin proteins; 3) inhibits interactions between Itgb1/Itgb3 subunits, PTK2, and talin and PTGER2/PTGER4 proteins through beta-arrestin-1 and Src kinase protein complex in human endometriotic epithelial cells 12Z and stromal cells 22B; and 4) decreases adhesion of 12Z and 22B cells to ECM collagen I, collagen IV, fibronectin, and vitronectin in a substrate-specific manner. These novel findings provide an important molecular framework for further evaluation of selective inhibition of PTGER2 and PTGER4 as potential nonsteroidal therapy to expand the spectrum of currently available treatment options for endometriosis in child-bearing age women.
子宫内膜异位症是一种发生于育龄期女性的慢性妇科疾病,其特征是子宫腔外存在功能性子宫内膜组织。内异症细胞与腹膜细胞外基质蛋白(ECM)之间的相互作用是允许内异症细胞黏附到腹膜间皮的关键机制。前列腺素 E2(PGE2)在子宫内膜异位症的发病机制中起着重要作用。在以前的研究中,我们已经报道了选择性抑制 PGE2 受体 PTGER2 和 PTGER4 通过多种机制降低人子宫内膜异位症上皮和基质细胞的存活和侵袭。本研究的结果表明,选择性抑制 PTGER2 和 PTGER4 介导的 PGE2 信号转导:1)降低特定整合素受体亚基 Itgb1(β1)和 Itgb3(β3)的表达和/或活性,但不降低 Itgb5(β5)、Itga1(α1)、Itga2(α2)、Itga5(α5)和 Itgav(αv)的表达和/或活性;2)降低整合素信号成分粘着斑激酶或蛋白激酶 2(PTK2)和塔林蛋白;3)抑制人子宫内膜异位症上皮细胞 12Z 和基质细胞 22B 中 Itgb1/Itgb3 亚基、PTK2 和塔林与 PTGER2/PTGER4 蛋白之间的相互作用通过β-arrestin-1 和Src 激酶蛋白复合物;4)以基质特异性方式降低 12Z 和 22B 细胞与 ECM 胶原 I、胶原 IV、纤连蛋白和 vitronectin 的黏附。这些新发现为进一步评估选择性抑制 PTGER2 和 PTGER4 作为潜在的非甾体治疗方法提供了重要的分子框架,以扩大目前可用于育龄期女性子宫内膜异位症的治疗选择范围。